查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596449

骨骼發育不良市場：按類型、治療和最終用戶分類 - 全球預測 2025-2030

Skeletal Dysplasia Market by Type (Achondroplasia, Fibrodysplasia Ossificans Progressive, Hypophosphatasia), Treatment (Medication, Surgery), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年骨骼發育不良市場價值為28.3億美元，預計到2024年將達到30.3億美元，複合年成長率為7.20%，到2030年將達到46.1億美元。

骨骼發育不良包括一組以骨骼和軟骨生長異常為特徵的遺傳性疾病，導致身材矮小和各種骨骼異常。骨骼發育不良市場是由對準確診斷、治療方案以及基因檢測和分子診斷的進步日益成長的需求所推動的。這些疾病需要專門的醫療干預，使其成為醫療保健提供者、研究人員和製藥公司的重要市場。應用包括診斷影像、遺傳諮詢以及基因治療和標靶藥物等創新治療方法。該市場主要面向醫院、研究中心和專科診所。關鍵的成長要素包括由於檢出率提高、對罕見遺傳疾病認知的提高以及基因組學和個人化醫療的技術進步而導致盛行率增加。潛在的商機在於開發新療法、提高診斷準確性以及利用 CRISPR 和其他基因編輯技術。企業應專注於與基因研究機構合作，投資針對特定突變的罕見疾病藥物的研發。然而，市場成長面臨限制，包括治療成本上升、孤兒藥物核准的監管障礙以及對罕見疾病異質性的了解有限。挑戰包括對基因治療的倫理擔憂以及患者對現有治療方法的不同反應。創新機會包括非侵入性基因檢測、病患管理預測分析和骨再生研究。公司應該投資擴大產品範圍，包括客製化基因測試，並與醫療保健 IT 公司合作，整合人工智慧進行預測診斷。該市場是研究集中市場，並受到監管環境的影響，在精準醫學進步的支持下，個人化治療計劃成為趨勢。為了取得成功，公司必須駕馭複雜的監管途徑，同時確保患者可近性並實施強調早期準確診斷價值的意識計劃。

主要市場統計
基準年[2023] 28.3億美元
預測年份 [2024] 30.3億美元
預測年份 [2030] 46.1億美元
複合年成長率（%） 7.20%

市場動態：快速發展的骨骼發育不良市場的關鍵市場洞察

供需的動態交互作用正在改變骨骼發育不良市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 先天性疾病和出生缺陷的增加
    • 荷爾蒙療法治療骨骼發育不良的進展
    • 關注骨骼發育不良設備的技術進步
  • 市場限制因素
    • 骨骼發育不良的治療選擇有限
  • 市場機會
    • 增加骨骼發育不良藥物開發的研發和臨床試驗
  • 市場挑戰
    • 缺乏有效的診斷工具和技術

波特五力：開拓骨骼發育不良市場的策略工具

波特的五力框架是了解骨骼發育不良市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解骨骼發育不良市場的外部影響

外部宏觀環境因素在塑造骨骼發育不良市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解骨骼發育不良市場的競爭狀況

對骨骼發育不良市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣骨骼發育不良市場供應商的績效評估

FPNV 定位矩陣是評估骨骼發育不良市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製骨骼發育不良市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對骨骼發育不良市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 先天性疾病和出生缺陷的增加
      • 荷爾蒙療法治療骨骼發育不良的進展
      • 關注骨骼發育不良設備的技術進步
    • 抑制因素
      • 骨骼發育不良的治療選擇有限
    • 機會
      • 增加藥物開發的研發和臨床試驗骨骼發育不良
    • 任務
      • 缺乏有效的診斷工具和技術
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章骨骼發育不良市場：依類型

  • 軟骨發育不全
  • 進行性肌肉骨化症
  • 低磷酸酯酶症
  • 多發性骨軟骨瘤
  • X連鎖低血磷症

第7章 骨骼發育不良市場治療市場治療

  • 藥物治療
  • 外科手術

第8章骨骼發育不良市場：依最終用戶分類

  • 診所
  • 醫院

第9章北美及南美骨骼發育不良市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區骨骼發育不良市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的骨骼發育不良市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alexion Pharmaceuticals Inc.
  • Amgen, Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • BioMarin Pharmaceutical Inc.
  • Celgene Corporation
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-AD36CD89842F

The Skeletal Dysplasia Market was valued at USD 2.83 billion in 2023, expected to reach USD 3.03 billion in 2024, and is projected to grow at a CAGR of 7.20%, to USD 4.61 billion by 2030.

Skeletal dysplasia encompasses a group of genetic disorders characterized by abnormalities in bone and cartilage growth, leading to disproportionate short stature and various skeletal anomalies. The market for skeletal dysplasia is driven by the growing need for accurate diagnosis, treatment options, and advancements in genetic testing and molecular diagnostics. These disorders necessitate specialized medical interventions, making the market critical for healthcare providers, researchers, and pharmaceutical companies. The application scope includes diagnostic imaging, genetic counseling, and innovative therapeutic approaches like gene therapy and targeted drugs. The market caters primarily to hospitals, research centers, and specialty clinics. Key growth factors include increasing prevalence due to improved detection rates, heightened awareness of rare genetic disorders, and technological advancements in genomics and personalized medicine. Potential opportunities lie in developing novel therapeutics, enhancing diagnostic accuracy, and leveraging CRISPR and other gene-editing technologies. Companies should focus on collaborations with genetic research institutions and invest in R&D for orphan drugs tailored to specific mutations. However, market growth faces limitations such as high costs of treatment, regulatory hurdles for orphan drug approvals, and limited understanding of disease heterogeneity due to its rarity. Challenging factors include ethical concerns regarding genetic treatments and variable patient responses to existing therapies. Innovation opportunities point towards non-invasive genetic testing, predictive analytics for patient management, and bone regeneration research. Businesses should capitalize on expanding their product offerings to include tailored genetic tests and collaborate with healthcare IT firms to integrate AI for predictive diagnostics. The market is research-intensive and shaped by regulatory landscapes, with a trend moving towards personalized treatment plans supported by advancements in precision medicine. To succeed, companies must navigate complex regulatory pathways while ensuring patient accessibility and awareness programs that highlight the value of early and accurate diagnosis.

KEY MARKET STATISTICS
Base Year [2023] USD 2.83 billion
Estimated Year [2024] USD 3.03 billion
Forecast Year [2030] USD 4.61 billion
CAGR (%) 7.20%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Skeletal Dysplasia Market

The Skeletal Dysplasia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing congenital disorders and birth defects
    • Growth in hormone therapy for treatment of skeletal dysplasia
    • Focus on the technological advancements in skeletal dysplasia devices
  • Market Restraints
    • Limited treatment options available for skeletal dysplasia
  • Market Opportunities
    • Increasing R&D and clinical trial for drug development of skeletal dysplasia
  • Market Challenges
    • Lack of efficient diagnostic measures and technologies

Porter's Five Forces: A Strategic Tool for Navigating the Skeletal Dysplasia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Skeletal Dysplasia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Skeletal Dysplasia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Skeletal Dysplasia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Skeletal Dysplasia Market

A detailed market share analysis in the Skeletal Dysplasia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Skeletal Dysplasia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Skeletal Dysplasia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Skeletal Dysplasia Market

A strategic analysis of the Skeletal Dysplasia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Skeletal Dysplasia Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen, Inc., ARUP Laboratories, AstraZeneca PLC, BioMarin Pharmaceutical Inc., Celgene Corporation, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Skeletal Dysplasia Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Achondroplasia, Fibrodysplasia Ossificans Progressive, Hypophosphatasia, Multiple Osteochondromas, and X-linked Hypophosphatemia.
  • Based on Treatment, market is studied across Medication and Surgery.
  • Based on End User, market is studied across Clinic and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing congenital disorders and birth defects
      • 5.1.1.2. Growth in hormone therapy for treatment of skeletal dysplasia
      • 5.1.1.3. Focus on the technological advancements in skeletal dysplasia devices
    • 5.1.2. Restraints
      • 5.1.2.1. Limited treatment options available for skeletal dysplasia
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D and clinical trial for drug development of skeletal dysplasia
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of efficient diagnostic measures and technologies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Skeletal Dysplasia Market, by Type

  • 6.1. Introduction
  • 6.2. Achondroplasia
  • 6.3. Fibrodysplasia Ossificans Progressive
  • 6.4. Hypophosphatasia
  • 6.5. Multiple Osteochondromas
  • 6.6. X-linked Hypophosphatemia

7. Skeletal Dysplasia Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medication
  • 7.3. Surgery

8. Skeletal Dysplasia Market, by End User

  • 8.1. Introduction
  • 8.2. Clinic
  • 8.3. Hospital

9. Americas Skeletal Dysplasia Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Skeletal Dysplasia Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Skeletal Dysplasia Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals Inc.
  • 3. Amgen, Inc.
  • 4. ARUP Laboratories
  • 5. AstraZeneca PLC
  • 6. BioMarin Pharmaceutical Inc.
  • 7. Celgene Corporation
  • 8. Cipla Inc.
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Company
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Novartis AG
  • 13. Regeneron Pharmaceuticals Inc.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. SKELETAL DYSPLASIA MARKET RESEARCH PROCESS
  • FIGURE 2. SKELETAL DYSPLASIA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SKELETAL DYSPLASIA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SKELETAL DYSPLASIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SKELETAL DYSPLASIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SKELETAL DYSPLASIA MARKET DYNAMICS
  • TABLE 7. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY ACHONDROPLASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY FIBRODYSPLASIA OSSIFICANS PROGRESSIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY HYPOPHOSPHATASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY MULTIPLE OSTEOCHONDROMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY X-LINKED HYPOPHOSPHATEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SKELETAL DYSPLASIA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES SKELETAL DYSPLASIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM SKELETAL DYSPLASIA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM SKELETAL DYSPLASIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM SKELETAL DYSPLASIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. SKELETAL DYSPLASIA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. SKELETAL DYSPLASIA MARKET, FPNV POSITIONING MATRIX, 2023